Biogen (United States)

Toward clinically actionable lupus biomarkers: a roadmap for research, validation, and translation

Abstract Despite advances in lupus biomarker research, clinical translation has remained limited, leading to delayed diagnosis, imprecise disease monitoring, and trial-and-error treatment approaches. This roadmap, developed by the Lupus Research Alliance’s Biomarker Roadmap Commi...

Genetic and pharmacologic inhibition of Keap1 dampens the pro-fibrotic program in human hepatic stellate cells

Abstract The increasing prevalence of chronic liver diseases (CLDs) is a global health concern. CLDs can cause fibrosis, and there is an urgent need for antifibrotic agents. The primary driver of fibrogenesis, transforming growth factor beta 1 (TGF-β1), activates hepatic stellate...

Toward actionable biomarkers in psychiatry: a collaborative roadmap for precision clinical trials. An ACNP position paper

Abstract Psychiatric drug development remains constrained by diagnostic heterogeneity, insufficient and inconsistent drug response, high placebo response rates, and the absence of validated biomarkers that can reliably guide patient stratification, trial design, and regulatory de...

Tebapivat: Pharmacokinetic Properties in Preclinical Species and Pharmacodynamic Responses Associated With Pyruvate Kinase Activation in Wild‐Type Mice

ABSTRACT The investigation of pyruvate kinase activating drugs is expanding into previously untested diseases as the benefits of increasing glycolytic flux within pyruvate kinase‐expressing tissues emerges. Recently, we reported the discovery of allosteric activator tebapivat, an...

Time-dependent divergence in infection risks among patients with multiple sclerosis treated with fumarates versus anti-CD20 monoclonal antibodies

Background: People with multiple sclerosis (pwMS) treated with anti-CD20 monoclonal antibodies have an elevated infection risk, yet long-term comparative data with oral fumarates are limited. Objective: To compare infection incidence, healthcare resource utilization, and relapse...

Fatal Neuroinvasive Astrovirus VA1 Encephalitis in a Child With High‐Risk B‐ALL Receiving Blinatumomab

O.L. is a named inventor on patents held by Boston Children's Hospital related to vaccine adjuvants and antigens as well as human in vitro systems that model the safety and immunogenicity of vaccines and immunotherapeutics. O.L.’s laboratory receives sponsored research support fr...